Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 16/20 | 0.74 |
| ▸ | IMPDH1 | P20839 | 7/20 | 0.74 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.67 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.58 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496013 | 0.94 | IMPDH2 (0.74) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL13917796 | 0.91 | IMPDH2 (0.71) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL14039597 | 0.90 | IMPDH2 (0.73) | IMPDH2IMPDH1AAK1ROCK2ROCK1 | |
| SCHEMBL12300716 | 0.88 | IMPDH2 (0.70) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL12343257 | 0.88 | IMPDH2 (0.76) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL23948366 | 0.88 | IMPDH2 (0.69) | IMPDH2IMPDH1AAK1ROCK2ROCK1 | |
| SCHEMBL12828059 | 0.88 | IMPDH2 (0.69) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL7214976 | 0.87 | IMPDH2 (0.74) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL12344525 | 0.87 | IMPDH2 (0.56) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL12342857 | 0.87 | IMPDH2 (0.68) | IMPDH2IMPDH1AAK1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017223178-A1 | TREATING VIRAL INFECTIONS WITH IMPDH INHIBITORS | TREK THERAPEUTICS, PBC (US) | 2017-12-28 | — | — | WO | disclosed |
| US-8268873-B2 | Use of 1-Cyanobutan-2-yl-1-[3-[3-[3-methoxy-4-(oxazol-5-yl)phenyl]ureido]phenyl] ethylcarbamate, AVN 944, VX-944 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-05-03 | — | — | US | disclosed |
| US-7943593-B2 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors comprising a substituted carbamate-functional N,N'-diphenylurea of given formula; and an apoptosis-inducing anticancer agent such as methotrexate in a synergistic mixture; treating cancer, tumors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-17 | — | — | US | disclosed |
| US-7915255-B2 | Metabolism-modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2011-03-29 | — | — | US | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20090030051-A1 | Inhibitors of IMPDH enzyme | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-29 | — | — | US | disclosed |
| EP-2009004-A1 | NOVEL PIPERAZINE COMPOUND, AND USE THEREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
| EP-1964561-A1 | Inhibitors of IMPDH enzyme | Vertex Pharmaceuticals Incorporated (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | JAPAN TOBACCO INC. (JP) | 2008-04-03 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070032497-A1 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-7112600-B1 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2006-09-26 | — | — | US | disclosed |
| EP-1688420-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2006-08-09 | — | — | EP | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| US-20040082635-A1 | Viricide against hepatitis virus; polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1400241-A1 | FUSED CYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | HAVCR2, AADAC, DNPEP | IMPDH2 183/4885IMPDH1 125/4885AAK1 2278/4885 |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | IMPDH2 836/4885IMPDH1 541/4885AAK1 2596/4885 |
| US-20040082635-A1 | Viricide against hepatitis virus; polymerase inhibitor | HAVCR2, ZC3HAV1, POLR1C | IMPDH2 322/4885IMPDH1 108/4885AAK1 1913/4885 |
| US-20070032497-A1 | Fused-ring compounds and use thereof as drugs | HAVCR2, ZC3HAV1, HLA-C | IMPDH2 586/4885IMPDH1 465/4885AAK1 3240/4885 |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | IMPDH2 477/4885IMPDH1 326/4885AAK1 1248/4885 |
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | POLR1C, POLR2E, POLR2H | IMPDH2 262/4885IMPDH1 175/4885AAK1 2224/4885 |
| US-20090030051-A1 | Inhibitors of IMPDH enzyme | IMPDH1, IMPDH2, IMPA1 | IMPDH2 2/4885IMPDH1 1/4885AAK1 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.